



Markets
/
Stocks
/
nasdaq-namsw
/

NewAmsterdam Pharma Company NV

NAMSW

View Detailed Chart

7.910USD

-0.090-1.13%

Close 04/23, 16:00（ET）Quotes delayed by 15 min

0.00Market Cap

--P/E TTM



NewAmsterdam Pharma Company NV

7.910

-0.090-1.13%

Company

Intraday

30m

Today

-1.13%

5 Days

+5.47%

1 Month

-40.03%

6 Months

-8.45%

Year to Date

-44.49%

1 Year

-16.56%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(4)

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.307

Neutral

RSI(14)

51.138

Neutral

STOCH(KDJ)(9,3,3)

73.212

Neutral

ATR(14)

0.866

High Vlolatility

CCI(14)

137.015

Buy

Williams %R

27.654

Buy

TRIX(12,20)

-0.819

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

8.008

Sell

MA10

7.478

Buy

MA20

7.879

Buy

MA50

8.394

Sell

MA100

9.311

Sell

MA200

8.168

Sell

News

More news coming soon, stay tuned...

Company

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Company codeNAMSW

CompanyNewAmsterdam Pharma Company NV

CEODr. Michael Harvey Davidson, M.D.

Websitehttps://ir.newamsterdampharma.com/